Compare McKesson Corporation (MCK) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Microsoft — how do they compare? McKesson Corporation trades at $829.95 (market cap $97.35B), while Microsoft trades at $397.8 (market cap $2.99T). The key difference: Microsoft is far larger — about 30.7× McKesson Corporation's market cap, and Microsoft pays the higher dividend (0.9%). Which is the better fit depends on your goals.
| MCK | MSFT | |
|---|---|---|
Market Cap | $97.35B | $2.99T |
Sector | Health | Technology |
52-Week High | $995.69 | $542.07 |
52-Week Low | $659.01 | $352.83 |
Enterprise Value | $101.98B | $2.97T |
Dividend Yield | 0.39% | 0.9% |
Volume | — | 36,654,621 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Microsoft (MSFT) trades at $393.82, down 1.82% over the past day, with a bullish technical signal from moving averages and support near $390. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $4.27 exceeding the $4.06 estimate. Revenue growth remains robust, reaching $281.72 billion in 2025, and analyst sentiment is overwhelmingly positive with an 80.49% buy rating.
The outlook for MSFT is favorable, driven by AI leadership, cloud momentum, and consistent profitability, though risks include elevated capital expenditure concerns and competitive pressures. The consensus price target of $546.70 implies significant upside, supported by solid cash flow generation and a strong balance sheet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
